Britain and America have agreed to a major bilateral deal that will maintain zero duties on UK pharmaceutical exports entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to raise spending on pharmaceuticals through the National Health Service (NHS). This move guarantees that import taxes on these key goods will remain at nothing for a timeframe of 36 months.
This agreement is in response to earlier threats to hike import taxes on patented pharmaceutical products, with increases discussed up to one hundred percent.
"This arrangement between the United Kingdom reinforces the international landscape for cutting-edge drugs and establishes much-needed balance to U.S.–U.K. medicine commerce," a release said.
Trade Importance
Drugs represent one of the the United Kingdom's most significant exports to the US, which is by far the biggest market for major British pharmaceutical firms.
Export figures reveal that in the one-year period prior to the third quarter, the UK sold drugs totaling £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that span.
"This agreement protects employment, stimulates funding and sets the stage for the UK to become a global hub for biotech and pharma," a minister remarked.
Detailed British Pledges
The agreement entails several notable pledges from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to increase overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount drug companies must return to the NHS to control costs will be limited at 15%. Last year, refunds exceeded 20%.
Industry Background
This agreement follows a long-running tension between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
This friction were intensified by arguments that US consumers were charged significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several large drug company projects in the UK have been paused or scrapped, while multi-billion-dollar expansions have been pledged toward American operations.
A senior figure stated that the NHS had to increase expenditure on treatments, noting that its budget allocation on drugs had declined as a share of its resources over the past decade.
